| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Jun, 2020 | Mar, 2020 | Jun, 2019 |
| Sales | 75,806 | 81,556 | 55,195 | 51,570 | 50,029 |
| Sales Growth | -7.05% | +47.76% | +7.03% | +3.08% | -4.10% |
| Net Income | -61,254 | -41,143 | -33,553 | -16,141 | -25,484 |
| Net Income Growth | -48.88% | -22.62% | -107.87% | +36.66% | -28.16% |
Hutchmed [China] Limited (HCM.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Fiscal Year End Date: 12/31